We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals

53 hedge funds and large institutions have $112M invested in Verrica Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more call options, than puts

Call options by funds: $3K | Put options by funds: $2K

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

4% more funds holding

Funds holding: 5153 (+2)

0.01% more ownership

Funds ownership: 3.61%3.63% (+0.01%)

25% less capital invested

Capital invested by funds: $150M → $112M (-$38.1M)

39% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 18

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
53
Holders Change
+2
Holders Change %
+3.92%
% of All Funds
0.92%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
11
Reduced
18
Closed
9
Calls
$3K
Puts
$2K
Net Calls
+$1K
Net Calls Change
+$1K

VRCA Hedge Fund Activity: Q2 2021 in Review

53 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2021, worth a combined $112M — down 25% from $150M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new VRCA positions and 9 closed out — a net gain of 2 holders — while 11 added to existing stakes and 18 trimmed.

The largest buyer was Millennium Management, adding an estimated $3.47M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $3.03M sold.

  • 53 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2021, up from 51 in Q1 2021.
  • Funds reported $112M of Verrica Pharmaceuticals stock for Q2 2021, down 25% quarter-over-quarter.
  • 11 funds opened new Verrica Pharmaceuticals positions in Q2 2021 and 9 closed out, a net change of +2 holders.
  • The largest Verrica Pharmaceuticals buyer in Q2 2021 was Millennium Management, an estimated $3.47M added.
  • The largest Verrica Pharmaceuticals seller in Q2 2021 was Monashee Investment Management, an estimated $3.03M sold.

Based on aggregated 13F filings for Q2 2021.